There’s been increasing attention on the little known organism Mycoplasma genitalium as an emerging cause of sexually transmitted conditions in women and men. If left untreated in women, it can cause pelvic inflammatory disease, infertility and has been associated with preterm delivery and miscarriage.
What makes M. genitalium so challenging to manage is its limited susceptibility to available classes of antimicrobials and the rapid emergence of multidrug resistance. Resistance guided therapy is a new but essential approach to effective treatment and control of M. genitalium.
While we still need to learn more about M.genitalium, it is so important to keep up to date with the latest practical recommendations to manage this newly discovered infectious bacterium. To that end, we have created a KISS (Keep It Simple Summary) for you, based on the recently updated Australasian Sexual Health Alliance (ASHA) Australian STI Management Guidelines for Use in Primary Care. The infection is often misdiagnosed as chlamydia and treated as such, which encourages antimicrobial resistance. Now that we are able to accurately test for M.genitalium, we need to tailor treatment to help minimise resistance in the Australian setting.
Hot Topics Courses
Our 2019 tour of Hot Topics courses commences 23 February through to 30 March. Click here for the details.
Participants of the one-day course are eligible for 12 Category 2 RACGP QI&CPD Points and 6 CPD hours for Nurses. Participants who complete a post-course activity will be eligible for 40 Category 1 RACGP QI&CPD Points. Certificates of completion can be provided for other health professionals requiring evidence of participation.